This study, co-authored by Dr. Ethan Russo was published in Cannabis & Cannabinoid Research in September 2021. It explored the self-reported effectiveness in CBG dominant cannabis or hemp products.
This study consisted of online surveys from 127 adult respondents who used CBG dominant cannabis for medical and/or adult use. The conditions treated were anxiety (51%), chronic pain (41%), depression (33%), and insomnia/disturbed sleep (31%).
One interesting aspect of this survey is that the vast majority of respondents reported that their CBG product was superior to traditional pharmaceuticals. The results are probably best summarized with a quote from the authors:
"Efficacy was highly rated, with the majority reporting their conditions were "very much improved" or "much improved" by CBG. Furthermore, 73.9% claimed superiority of CBG-predominant cannabis over conventional medicines for chronic pain, 80% for depression, 73% for insomnia, and 78.3% for anxiety."
The paper abstract is here at PubMed.gov.